Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jose Maria, Auge"'
Autor:
Rafael Molina, Massimo Gion, Axel Gressner, Frédéric Troalen, Jose Maria Auge, Stefan Holdenrieder, Matelda Zancan, Matthias Wycislo, Petra Stieber
Publikováno v:
Clinical Chemistry and Laboratory Medicine. 46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdc02e955e180af8170d958228a40179
https://doi.org/10.1515/cclm.2008.133
https://doi.org/10.1515/cclm.2008.133
Autor:
Stefan, Holdenrieder, Rafael, Molina, Massimo, Gion, Axel, Gressner, Frédéric, Troalen, Jose Maria, Auge, Matelda, Zancan, Matthias, Wycislo, Petra, Stieber
Publikováno v:
Clinical Chemistry and Laboratory Medicine. 46
Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer.The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d6eb3c5476540b14f467ea3e947122
https://doi.org/10.1515/cclm.2008.125
https://doi.org/10.1515/cclm.2008.125
Autor:
Petra Stieber, Rafael Molina, Massimo Gion, Axel Gressner, Frédéric Troalen, Stefan Holdenrieder, Jose Maria Auge, Matelda Zancan, Matthias Wycislo, Véronique Jarrige
Publikováno v:
Clinical Chemistry and Laboratory Medicine. 46
Background: Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer. Methods: The analytical and clinical performance of the Access' BR Monitor Immunoassay System (Beckman Coulter) was evaluated at five differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652e460fcf826416eb8f4e721df43b45
https://doi.org/10.1515/cclm.2008.126
https://doi.org/10.1515/cclm.2008.126
Autor:
J. Domingo-Domenech, Manuel Bernal-Sprekelsen, Wladimiro Jiménez, Miguel Caballero, Jose Maria Auge, José Luis Blanch, Juan J. Grau
Publikováno v:
Archives of Otolaryngology–Head & Neck Surgery. 133:1143
To evaluate serum vascular endothelial growth factor (VEGF) as a prognostic factor in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with metronomic (weekly) paclitaxel.Before-and-after trial.A total of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c431e19d183d5678b1705f8a66241f
https://doi.org/10.1001/archotol.133.11.1143
https://doi.org/10.1001/archotol.133.11.1143